A vaccine against Covid-19 in the form of a nasal spray achieved promising results in tests conducted by researchers at the University of Georgia, USA.
The inhaler reduced the risk of symptomatic COVID-19 infection by up to 86 percent in people who received the vaccine as a booster dose.
According to the researchers, the inhaler, which is still under testing, has so far proven to be more effective than the booster doses that are given as injections.
The researchers said that the vaccines taken through the nose in the form of a spray produced distinctive results, due to their ability to activate immune cells in the mucous membranes that line the nasal and oral cavities, as the coronavirus first enters the body through these outlets.
What are the advantages of the aerosol vaccine?
- The aerosol vaccine was developed by the American company, “Blue Lake Biotechnology”, and focuses on immune protection in the upper airways.
- The spray puts powerful antibodies right on the front lines of the coronavirus.
- The aerosol vaccine technology relies on a type of parainfluenza virus encoded using the spike protein to train the immune system to recognize and fight it.
- Once the contents of the vaccine are inhaled, small parts of the parainfluenza virus multiply within a cavity to trigger an immune response without making the person sick.
- Statistics show that booster vaccines currently in use across the United States reduce infections associated with Covid-19 by 43 percent in people 65 years of age or younger during roughly the same time period that the spray provides 86 percent protection, according to the Daily Mail. British Mile.
